Neuralace Medical, a pioneering company in the medical technology sector, has achieved a significant milestone with the recent US Food and Drug Administration (FDA) clearance of its innovative Axon Therapy.
This breakthrough is specifically targeted at treating chronic painful diabetic neuropathy (PDN), a condition affecting a substantial number of diabetic patients.
PDN often manifests as a debilitating condition, characterised by symptoms such as a tingling sensation, numbness, and a burning feeling, often accompanied by an excruciating, stabbing type of pain.
This pain is typically localised in the feet or hands, leading to significant discomfort and a decrease in the quality of life for those affected.
Axon Therapy, developed by Neuralace Medical, represents a cutting-edge approach in the treatment of PDN.
It is a noninvasive magnetic peripheral nerve stimulation (mPNS) treatment. This innovative therapy employs the mPNS technique to administer a noninvasive treatment, only lasting about 13.5 minutes per session.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
Your download email will arrive shortly
We are confident about the
quality of our Company Profiles. However, we want you to make the most
decision for your business, so we offer a free sample that you can download by
submitting the below form
The essence of the therapy lies in its use of magnetic pulses, which are directed to alleviate the pain experienced by PDN patients.
This method stands as a significant advancement in the field of pain management, offering a new horizon for patients who have long sought relief from chronic neuropathic pain.
The effectiveness and reliability of Axon Therapy has been underscored by a comprehensive double-blind multicentre randomised controlled trial (RCT) that involved a total of 71 patients.
This pivotal study consisted of 50 participants receiving the active mPNS treatment and 21 individuals in a sham group.
Notably, participants in the sham group were given the opportunity to switch to the active treatment group after a period of 30 days, allowing for a comprehensive evaluation of the therapy’s efficacy.
The FDA clearance of Neuralace Medical’s Axon Therapy is not just a breakthrough in medical treatment but also signifies a paradigm shift in the management of PDN.
By offering a nonpharmacological and noninvasive alternative, this therapy presents a potential reduction in the dependence on medications and their associated side effects, which is often a concern for many patients.
This development opens the door to more accessible and innovative pain management solutions.
It highlights Neuralace Medical’s commitment to advancing patient care through technological innovation, striving to improve the lives of those suffering from chronic pain conditions.
As the medical community continues to evolve, the introduction of therapies such as Axon Therapy is a promising step towards more effective, patient-centric healthcare solutions.